Develops new drugs and medical devices, with a focus on oncology, central nervous system, and ophthalmology treatments.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Fremont, California, dedicated to developing innovative drugs and medical devices to address unmet medical needs across the United States. Established as a subsidiary of YuanGene Corporation, ABVC BioPharma focuses on advancing a diverse pipeline of therapeutic candidates aimed at tackling a range of challenging medical conditions.
At the forefront of ABVC BioPharma's portfolio is ABV-1501, currently undergoing Phase I/II clinical trials as a combination therapy for triple negative breast cancer. Additionally, the company has successfully completed Phase II trials for ABV-1504, targeting major depressive disorders, and is progressing ABV-1505 through Phase II trials for attention deficit hyperactivity disorder (ADHD). Furthermore, ABVC BioPharma has achieved significant milestones with ABV-1703 and ABV-1702, both completing Phase I trials for pancreatic cancer and myelodysplastic syndromes, respectively.
Collaboration plays a pivotal role in ABVC BioPharma's strategy, evidenced by coodevelopment agreements with Rgene Corporation, and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. These partnerships bolster the company's capabilities and broaden its scope in bringing novel treatments to patients in need, underscoring ABVC BioPharma's commitment to innovation and patient-centered healthcare solutions.